An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer We assessed cancer-related molecular marker test ...

HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based ...

HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...

The EML250-ID and OmniMarker-ID transform underground utility management into a data-driven system that can write, ...